Delay in NHS patients' access to cancer drug labelled a 'disgrace' Chief executive of lung cancer charity bemoans likely nine-month wait for immunotherapy drug nivolumab to be approved for NHS use
A delay in access to a drug that has been shown to double the life expectancy of some patients with lung cancer has been described as a “disgrace”.
Paula Chadwick, chief executive of Roy Castle Lung Cancer Foundation, said patients are unlikely to be able to take immunotherapy drug nivolumab until May 2016 at the earliest, which will be too late for some. Continue reading... The Guardian
See also:
A delay in access to a drug that has been shown to double the life expectancy of some patients with lung cancer has been described as a “disgrace”.
Paula Chadwick, chief executive of Roy Castle Lung Cancer Foundation, said patients are unlikely to be able to take immunotherapy drug nivolumab until May 2016 at the earliest, which will be too late for some. Continue reading... The Guardian
See also:
- Cancer treatment is delayed for a year by NHS red tape The Daily Mail
No comments:
Post a Comment